PriceTargets.com logo

iTeos Therapeutics - ITOS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.25
  • Forecasted Upside: 199.87%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$7.42 As of 12/20/2024 06:30 PM ET
▲ +0.2 (2.77%)

This chart shows the closing price for ITOS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New iTeos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ITOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ITOS

Analyst Price Target is $22.25
▲ +199.87% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for iTeos Therapeutics in the last 3 months. The average price target is $22.25, with a high forecast of $25.00 and a low forecast of $19.00. The average price target represents a 199.87% upside from the last price of $7.42.

This chart shows the closing price for ITOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in iTeos Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/19/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$31.00 ➝ $19.00
12/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
12/12/2024WedbushReiterated RatingOutperform$25.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
11/12/2024WedbushReiterated RatingOutperform$25.00
9/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
8/13/2024Wells Fargo & CompanyInitiated CoverageOverweight$31.00
8/12/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$27.00 ➝ $24.00
8/8/2024WedbushReiterated RatingOutperform$21.00
6/17/2024WedbushReiterated RatingOutperform$21.00
5/13/2024HC WainwrightBoost TargetBuy ➝ Buy$44.00 ➝ $46.00
3/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$44.00
3/6/2024WedbushReiterated RatingOutperform$25.00 ➝ $18.00
1/8/2024WedbushReiterated RatingOutperform$33.00
11/13/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$32.00 ➝ $29.00
11/7/2023WedbushReiterated RatingOutperform$33.00
10/18/2023WedbushReiterated RatingOutperform ➝ Outperform$33.00
8/9/2023HC WainwrightLower TargetBuy ➝ Buy$54.00 ➝ $44.00
8/8/2023WedbushReiterated RatingOutperform$33.00
3/17/2023HC WainwrightReiterated RatingBuy$54.00
3/16/2023JPMorgan Chase & Co.Lower TargetOverweight$34.00 ➝ $32.00
3/16/2023WedbushLower TargetOutperform$45.00 ➝ $33.00
5/11/2022Piper SandlerLower Target$42.00 ➝ $34.00
12/13/2021HC WainwrightBoost TargetBuy ➝ Buy$37.00 ➝ $54.00
11/12/2021Leerink PartnersLower TargetOutperform$55.00 ➝ $54.00
11/11/2021Piper SandlerLower TargetOverweight$50.00 ➝ $42.00
8/13/2021Leerink PartnersLower TargetOutperform$56.00 ➝ $55.00
5/19/2021Leerink PartnersLower TargetOutperform$60.00 ➝ $45.00
5/5/2021HC WainwrightInitiated CoverageBuy$37.00
4/6/2021Leerink PartnersBoost TargetOutperform$37.00 ➝ $60.00
3/25/2021WedbushBoost TargetOutperform$46.00 ➝ $52.00
11/19/2020Leerink PartnersBoost TargetOutperform$36.00 ➝ $37.00
10/7/2020Robert W. BairdInitiated CoverageOutperform$45.00
8/18/2020JPMorgan Chase & Co.Initiated CoverageOverweight$40.00
8/18/2020Leerink PartnersInitiated CoverageOutperform$36.00
8/18/2020WedbushInitiated CoverageOutperform$45.00
8/18/2020Piper SandlerInitiated CoverageOverweight$50.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

iTeos Therapeutics logo
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $7.42
Low: $7.09
High: $7.51

50 Day Range

MA: $8.54
Low: $7.22
High: $9.73

52 Week Range

Now: $7.42
Low: $7.09
High: $18.75

Volume

2,443,768 shs

Average Volume

452,593 shs

Market Capitalization

$271.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of iTeos Therapeutics?

The following Wall Street analysts have issued research reports on iTeos Therapeutics in the last twelve months: HC Wainwright, JPMorgan Chase & Co., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for ITOS.

What is the current price target for iTeos Therapeutics?

0 Wall Street analysts have set twelve-month price targets for iTeos Therapeutics in the last year. Their average twelve-month price target is $22.25, suggesting a possible upside of 199.9%. Wedbush has the highest price target set, predicting ITOS will reach $25.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $19.00 for iTeos Therapeutics in the next year.
View the latest price targets for ITOS.

What is the current consensus analyst rating for iTeos Therapeutics?

iTeos Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ITOS will outperform the market and that investors should add to their positions of iTeos Therapeutics.
View the latest ratings for ITOS.

What other companies compete with iTeos Therapeutics?

Other companies that are similar to iTeos Therapeutics include Rocket Pharmaceuticals, Bicycle Therapeutics, Avadel Pharmaceuticals, Collegium Pharmaceutical and Septerna. Learn More about companies similar to iTeos Therapeutics.

How do I contact iTeos Therapeutics' investor relations team?

The company's listed phone number is 339-217-0161 and its investor relations email address is [email protected]. The official website for iTeos Therapeutics is www.iteostherapeutics.com. Learn More about contacing iTeos Therapeutics investor relations.